No Picture
News

Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced today that it has d… […]

No Picture
News

City of San Diego Proclaims mRNA Day in Celebration of New Maravai LifeSciences Headquarters

The new facility will house TriLink BioTechnologies, a Maravai LifeSciences company, and a state-of-the-art biotech manufacturing facility

SAN DIEGO, Nov. 20, 2019 /PRNewswire/ — mRNA Day is being celebrated in the City of San Diego following a proc… […]

No Picture
News

Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks

SAN DIEGO, Nov. 19, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical compan… […]

No Picture
News

DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended S… […]

No Picture
News

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

SAN DIEGO, Nov. 13, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the “Company”), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal … […]